Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 72% of modeled bridge. Strengths: Revenue per Bed, Bed Count. Risks: Net-to-Gross Ratio, Commercial Payer %. Risk-adjusted uplift: $4.8M (vs $6.6M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $2.5M | $2.5M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $2.4M | $69K | $2.5M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $383K | $1.1M | $1.5M | $4.8M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $80K | $80K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 62.3% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $623K | $1.2M | $1.9M | $2.5M | $2.5M | $2.5M | $2.5M |
| Denial Rate Reduction | $0 | $617K | $1.2M | $1.9M | $2.5M | $2.5M | $2.5M | $2.5M |
| A/R Days Reduction | $0 | $506K | $1.0M | $1.5M | $1.5M | $1.5M | $1.5M | $1.5M |
| Clean Claim Rate | $0 | $40K | $80K | $80K | $80K | $80K | $80K | $80K |
| Cumulative | $0 | $1.8M | $3.6M | $5.3M | $6.6M | $6.6M | $6.6M | $6.6M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $6.6M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 176% / 160.8x | 182% / 179.0x | 188% / 197.3x | 190% / 206.4x | 193% / 215.5x |
| 9.0x | 170% / 142.6x | 176% / 158.8x | 181% / 175.0x | 183% / 183.1x | 186% / 191.2x |
| 10.0x | 164% / 128.0x | 170% / 142.6x | 175% / 157.2x | 177% / 164.5x | 180% / 171.8x |
| 11.0x | 159% / 116.1x | 164% / 129.3x | 170% / 142.6x | 172% / 149.2x | 174% / 155.8x |
| 12.0x | 154% / 106.1x | 160% / 118.3x | 165% / 130.4x | 167% / 136.5x | 170% / 142.6x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 94% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 0.4x, adding 8.1 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $308K | — | $308K | 0.2% |
| Year 1 | $317K | +$4.4M | $4.7M | 3.8% |
| Year 2 | $327K | +$6.6M | $6.9M | 5.5% |
| Year 3 | $337K | +$6.6M | $6.9M | 5.5% |
| Year 4 | $347K | +$6.6M | $6.9M | 5.5% |
| Year 5 | $357K | +$6.6M | $6.9M | 5.5% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $1.2M | $1.9M | $2.5M | $3.0M |
| Denial Rate Reductio | $1.2M | $1.9M | $2.5M | $3.0M |
| A/R Days Reduction | $758K | $1.1M | $1.5M | $1.8M |
| Clean Claim Rate | $40K | $60K | $80K | $96K |
| Total | $3.3M | $4.9M | $6.6M | $7.9M |
Peer Context — Where This Hospital Sits
Key metrics vs 93 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 0.2% | -9.5% | -2.4% | 3.4% | P58 |
| Net-to-Gross | 63.3% | 47.6% | 56.3% | 62.3% | P78 |
| Occupancy | 53.7% | 16.5% | 33.7% | 44.8% | P84 |
| Rev/Bed | $5.0M | $1.1M | $1.9M | $2.7M | P95 |
| Exp/Bed | $5.0M | $1.1M | $1.8M | $2.8M | P95 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.